14 items matching your search terms.
-
Bisphosphonate drugs have actions in the lung and inhibit the mevalonate pathway in alveolar macrophages
- Munoz, M. A.; Fletcher, E. K.; Skinner, O. P.; Jurczyluk, J.; Kristianto, E.; Hodson, M. P.; Sun, S.; Ebetino, F. H.; Croucher, D. R.; Hansbro, P. M.; Center, J. R.; Rogers, M. J.
-
eLife
10
:e72430,
2021
10.7554/eLife.72430
-
Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton
- Rogers, M. J.; Monkkonen, J.; Munoz, M. A.
-
BONE
139
:115493,
2020
10.1016/j.bone.2020.115493
-
Defective Protein Prenylation in a Spectrum of Patients With Mevalonate Kinase Deficiency
- Munoz, M. A.; Jurczyluk, J.; Simon, A.; Hissaria, P.; Arts, R. J. W.; Coman, D.; Boros, C.; Mehr, S.; Rogers, M. J.
-
Frontiers in Immunology
10
:1900,
2019
10.3389/fimmu.2019.01900
-
Lack of protein prenylation promotes NLRP3 inflammasome assembly in human monocytes
- Skinner, O. P.; Jurczyluk, J.; Baker, P. J.; Masters, S. L.; Rios Wilks, A. G.; Clearwater, M. S.; Robertson, A. A. B.; Schroder, K.; Mehr, S.; Munoz, M. A.; Rogers, M. J.
-
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
143
(6)
:2315-2317 e3,
2019
10.1016/j.jaci.2019.02.013
-
From vesicle to cytosol
- Rogers, M. J.; Munoz, M. A.
-
eLife
7
:e38847,
2018
10.7554/eLife.38847
-
Defective protein prenylation is a diagnostic biomarker of mevalonate kinase deficiency
- Munoz, M. A.; Jurczyluk, J.; Mehr, S.; Chai, R. C.; Arts, R. J. W.; Sheu, A.; McMahon, C.; Center, J. R.; Singh-Grewal, D.; Chaitow, J.; Campbell, D. E.; Quinn, J. M. W.; Alexandrov, K.; Tnimov, Z.; Tangye, S. G.; Simon, A.; Phan, T. G.; Rogers, M. J.
-
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
140
(3)
:873-875.e6,
2017
10.1016/j.jaci.2017.02.033
-
A highly sensitive prenylation assay reveals in vivo effects of bisphosphonate drug on the Rab prenylome of macrophages outside the skeleton
- Ali, N.
; Jurczyluk, J.
; Shay, G.
; Tnimov, Z.
; Alexandrov, K.
; Munoz, M. A.
; Skinner, O. P.
; Pavlos, N. J.
; Rogers, M. J.;
-
Small GTPases
30
(4)
:637-46,
2015
-
Dynamics of bivalent chromatin domains upon drug induced reactivation and resilencing in cancer cells
- Mayor, R.; Munoz, M.; Coolen, M.W.; Custodio, J.; Esteller, M.; Clark, S.J.; Peinado, M.A.
-
Epigenetics
6
(9)
:1138-1148,
2011
-
The E3 Ubiquitin Ligase EDD Regulates S-Phase and G(2)/M DNA Damage Checkpoints
- Munoz, M. A.;Saunders, D. N.;Henderson, M. J.;Clancy, J. L.;Russell, A. J.;Lehrbach, G.;Musgrove, E. A.;Watts, C. K.;Sutherland, R. L. :
-
CELL CYCLE
6
(24)
:3070-3077,
2007
-
EDD mediates DNA damage-induced activation of CHK2
- Henderson, M. J.;Munoz, M. A.;Saunders, D. N.;Clancy, J. L.;Russell, A. J.;Williams, B.;Pappin, D.;Khanna, K. K.;Jackson, S. P.;Sutherland, R. L.;Watts, C. K. :
-
JOURNAL OF BIOLOGICAL CHEMISTRY
281
(52)
:39990-40000,
2006
-
Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a frequent event in colorectal cancer and associated with aneuploidy
- Frigola, J.;Munoz, M.;Clark, S. J.;Moreno, V.;Capella, G.;Peinado, M. A. :
-
ONCOGENE
24
(49)
:7320-6,
2005
-
EDD, the human hyperplastic discs protein, has a role in progesterone receptor coactivation and potential involvement in DNA damage response
- Henderson, M. J.;Russell, A. J.;Hird, S.;Munoz, M.;Clancy, J. L.;Lehrbach, G. M.;Calanni, S. T.;Jans, D. A.;Sutherland, R. L.;Watts, C. K. :
-
JOURNAL OF BIOLOGICAL CHEMISTRY
277
(29)
:26468-78,
2002
-
Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor
- Sautel, M.;Rudolf, K.;Wittneben, H.;Herzog, H.;Martinez, R.;Munoz, M.;Eberlein, W.;Engel, W.;Walker, P.;Beck-Sickinger, A. G. :
-
MOLECULAR PHARMACOLOGY
50
(2)
:285-92,
1996
-
High level expression of human neuropeptide Y receptors in mammalian cells infected with a recombinant vaccinia virus
- Walker, P.;Munoz, M.;Combe, M. C.;Grouzmann, E.;Herzog, H.;Selbie, L.;Shine, J.;Brunner, H. R.;Waeber, B.;Wittek, R. :
-
MOLECULAR AND CELLULAR ENDOCRINOLOGY
91
(1-2)
:107-12,
1993